Discovery of Novel-Scaffold Monoamine Transporter Ligands via in Silico Screening with the S1 Pocket of the Serotonin Transporter
Open Access
- 8 July 2014
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 5 (9) , 784-792
Abstract
Discovery of new inhibitors of the plasmalemmal monoamine transporters (MATs) continues to provide pharmacotherapeutic options for depression, addiction, attention deficit disorders, psychosis, narcolepsy, and Parkinson’s disease. The windfall of high-resolution MAT structural information afforded by X-ray crystallography has enabled the construction of credible computational models. Elucidation of lead compounds, creation of compound structure–activity series, and pharmacologic testing are staggering expenses that could be reduced by using a MAT computational model for virtual screening (VS) of structural libraries containing millions of compounds. Here, VS of the PubChem small molecule structural database using the S1 (primary substrate) ligand pocket of a serotonin transporter homology model yielded 19 prominent “hit” compounds. In vitro pharmacology of these VS hits revealed four structurally unique MAT substrate uptake inhibitors with high nanomolar affinity at one or more of the three MATs. In vivo characterization of three of these hits revealed significant activity in a mouse model of acute depression at doses that did not elicit untoward locomotor effects. This constitutes the first report of MAT inhibitor discovery using exclusively the primary substrate pocket as a VS tool. Novel-scaffold MAT inhibitors offer hope of new medications that lack the many classic adverse effects of existing antidepressant drugs.Keywords
Funding Information
- National Institutes of Health (DA026530, DA027806)
- American Pain Society
This publication has 64 references indexed in Scilit:
- Ligand Induced Conformational Changes of the Human Serotonin Transporter Revealed by Molecular Dynamics SimulationsPLOS ONE, 2013
- Short-term SSRI treatment normalises amygdala hyperactivity in depressed patientsPsychological Medicine, 2012
- X-ray structures of LeuT in substrate-free outward-open and apo inward-open statesNature, 2012
- Discovery of Novel Selective Serotonin Reuptake Inhibitors through Development of a Protein-Based PharmacophoreJournal of Chemical Information and Modeling, 2011
- Neurotransmitter/sodium symporter orthologue LeuT has a single high-affinity substrate siteNature, 2010
- Receptor-Based Discovery of a Plasmalemmal Monoamine Transporter Inhibitor via High-Throughput Docking and Pharmacophore ModelingACS Chemical Neuroscience, 2010
- Mechanism for Cocaine Blocking the Transport of Dopamine: Insights from Molecular Modeling and Dynamics SimulationsThe Journal of Physical Chemistry B, 2009
- Antidepressant specificity of serotonin transporter suggested by three LeuT–SSRI structuresNature Structural & Molecular Biology, 2009
- The binding sites for cocaine and dopamine in the dopamine transporter overlapNature Neuroscience, 2008
- The Mechanism of a Neurotransmitter:Sodium Symporter—Inward Release of Na+ and Substrate Is Triggered by Substrate in a Second Binding SiteMolecular Cell, 2008